Figures computed from official regulatory filings — .
Analysttarget 200 USD (+1333233%) · consensus 4.5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 4.07% · institutions 5.26% · short 2.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Vincerx Pharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
29 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| THOMAS TOM C | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Hamdy Ahmed MDtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Seelenberger Alexander A. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Seelenberger Alexander A. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Seelenberger Alexander A. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Hamdy Ahmed MDtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Seelenberger Alexander A. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Seelenberger Alexander A. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| THOMAS TOM C | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Seelenberger Alexander A. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Izumi Raquel E.track record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |